Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression

Lisa Sanderson Cox, Christi A. Patten, Raymond S. Niaura, Paul A. Decker, Nancy Rigotti, David P L Sachs, A (Sonia) Buist, Richard D. Hurt

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

BACKGROUND: This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. Changes in depressive symptoms were also examined. DESIGN: Data were gathered prospectively from a randomized, double-blind relapse prevention trial of bupropion conducted at five study sites. A total of 784 smokers (54% female, 97% white) were enrolled. Using the Structured Clinical Interview for Depression, 17% of the subjects reported a past history of major depressive disorder at baseline. All subjects received open-label bupropion SR (300 mg/d) for 7 weeks. Subjects abstinent from smoking at the end of 7 weeks (N = 429) were randomized to bupropion SR (300 mg/d) or placebo for the remainder of the year and followed for 1 year off medication. The primary outcome measures were median time to relapse to smoking and the 7-day point-prevalence smoking abstinence rate. Self-reported abstinence from smoking was verified by expired air carbon monoxide. The Beck Depression Inventory was used to assess depressive symptoms at baseline and at weeks 8 and 12. RESULTS: Median time to relapse did not differ by past history of major depressive disorder. Bupropion was associated with higher point-prevalence smoking abstinence at the end of medication compared to placebo (P = .007), independent of a past history of major depressive disorder. Moreover, change in depressive symptoms during the double-blind phase did not differ for those with and without a past history of major depressive disorder. CONCLUSIONS: Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression.

Original languageEnglish (US)
Pages (from-to)828-834
Number of pages7
JournalJournal of General Internal Medicine
Volume19
Issue number8
DOIs
StatePublished - Aug 2004

Fingerprint

Bupropion
Secondary Prevention
Major Depressive Disorder
Depression
Smoking
Placebos
Recurrence
Carbon Monoxide
Air
Outcome Assessment (Health Care)
Interviews
Equipment and Supplies

Keywords

  • Bupropion therapy
  • Major depression
  • Relapse prevention
  • Smoking

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Cox, L. S., Patten, C. A., Niaura, R. S., Decker, P. A., Rigotti, N., Sachs, D. P. L., ... Hurt, R. D. (2004). Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. Journal of General Internal Medicine, 19(8), 828-834. https://doi.org/10.1111/j.1525-1497.2004.30423.x

Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. / Cox, Lisa Sanderson; Patten, Christi A.; Niaura, Raymond S.; Decker, Paul A.; Rigotti, Nancy; Sachs, David P L; Buist, A (Sonia); Hurt, Richard D.

In: Journal of General Internal Medicine, Vol. 19, No. 8, 08.2004, p. 828-834.

Research output: Contribution to journalArticle

Cox, Lisa Sanderson ; Patten, Christi A. ; Niaura, Raymond S. ; Decker, Paul A. ; Rigotti, Nancy ; Sachs, David P L ; Buist, A (Sonia) ; Hurt, Richard D. / Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. In: Journal of General Internal Medicine. 2004 ; Vol. 19, No. 8. pp. 828-834.
@article{3c402f9bd9d84adf92110a0f724c73f9,
title = "Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression",
abstract = "BACKGROUND: This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. Changes in depressive symptoms were also examined. DESIGN: Data were gathered prospectively from a randomized, double-blind relapse prevention trial of bupropion conducted at five study sites. A total of 784 smokers (54{\%} female, 97{\%} white) were enrolled. Using the Structured Clinical Interview for Depression, 17{\%} of the subjects reported a past history of major depressive disorder at baseline. All subjects received open-label bupropion SR (300 mg/d) for 7 weeks. Subjects abstinent from smoking at the end of 7 weeks (N = 429) were randomized to bupropion SR (300 mg/d) or placebo for the remainder of the year and followed for 1 year off medication. The primary outcome measures were median time to relapse to smoking and the 7-day point-prevalence smoking abstinence rate. Self-reported abstinence from smoking was verified by expired air carbon monoxide. The Beck Depression Inventory was used to assess depressive symptoms at baseline and at weeks 8 and 12. RESULTS: Median time to relapse did not differ by past history of major depressive disorder. Bupropion was associated with higher point-prevalence smoking abstinence at the end of medication compared to placebo (P = .007), independent of a past history of major depressive disorder. Moreover, change in depressive symptoms during the double-blind phase did not differ for those with and without a past history of major depressive disorder. CONCLUSIONS: Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression.",
keywords = "Bupropion therapy, Major depression, Relapse prevention, Smoking",
author = "Cox, {Lisa Sanderson} and Patten, {Christi A.} and Niaura, {Raymond S.} and Decker, {Paul A.} and Nancy Rigotti and Sachs, {David P L} and Buist, {A (Sonia)} and Hurt, {Richard D.}",
year = "2004",
month = "8",
doi = "10.1111/j.1525-1497.2004.30423.x",
language = "English (US)",
volume = "19",
pages = "828--834",
journal = "Journal of General Internal Medicine",
issn = "0884-8734",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression

AU - Cox, Lisa Sanderson

AU - Patten, Christi A.

AU - Niaura, Raymond S.

AU - Decker, Paul A.

AU - Rigotti, Nancy

AU - Sachs, David P L

AU - Buist, A (Sonia)

AU - Hurt, Richard D.

PY - 2004/8

Y1 - 2004/8

N2 - BACKGROUND: This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. Changes in depressive symptoms were also examined. DESIGN: Data were gathered prospectively from a randomized, double-blind relapse prevention trial of bupropion conducted at five study sites. A total of 784 smokers (54% female, 97% white) were enrolled. Using the Structured Clinical Interview for Depression, 17% of the subjects reported a past history of major depressive disorder at baseline. All subjects received open-label bupropion SR (300 mg/d) for 7 weeks. Subjects abstinent from smoking at the end of 7 weeks (N = 429) were randomized to bupropion SR (300 mg/d) or placebo for the remainder of the year and followed for 1 year off medication. The primary outcome measures were median time to relapse to smoking and the 7-day point-prevalence smoking abstinence rate. Self-reported abstinence from smoking was verified by expired air carbon monoxide. The Beck Depression Inventory was used to assess depressive symptoms at baseline and at weeks 8 and 12. RESULTS: Median time to relapse did not differ by past history of major depressive disorder. Bupropion was associated with higher point-prevalence smoking abstinence at the end of medication compared to placebo (P = .007), independent of a past history of major depressive disorder. Moreover, change in depressive symptoms during the double-blind phase did not differ for those with and without a past history of major depressive disorder. CONCLUSIONS: Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression.

AB - BACKGROUND: This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. Changes in depressive symptoms were also examined. DESIGN: Data were gathered prospectively from a randomized, double-blind relapse prevention trial of bupropion conducted at five study sites. A total of 784 smokers (54% female, 97% white) were enrolled. Using the Structured Clinical Interview for Depression, 17% of the subjects reported a past history of major depressive disorder at baseline. All subjects received open-label bupropion SR (300 mg/d) for 7 weeks. Subjects abstinent from smoking at the end of 7 weeks (N = 429) were randomized to bupropion SR (300 mg/d) or placebo for the remainder of the year and followed for 1 year off medication. The primary outcome measures were median time to relapse to smoking and the 7-day point-prevalence smoking abstinence rate. Self-reported abstinence from smoking was verified by expired air carbon monoxide. The Beck Depression Inventory was used to assess depressive symptoms at baseline and at weeks 8 and 12. RESULTS: Median time to relapse did not differ by past history of major depressive disorder. Bupropion was associated with higher point-prevalence smoking abstinence at the end of medication compared to placebo (P = .007), independent of a past history of major depressive disorder. Moreover, change in depressive symptoms during the double-blind phase did not differ for those with and without a past history of major depressive disorder. CONCLUSIONS: Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression.

KW - Bupropion therapy

KW - Major depression

KW - Relapse prevention

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=4143147542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143147542&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1497.2004.30423.x

DO - 10.1111/j.1525-1497.2004.30423.x

M3 - Article

C2 - 15242467

AN - SCOPUS:4143147542

VL - 19

SP - 828

EP - 834

JO - Journal of General Internal Medicine

JF - Journal of General Internal Medicine

SN - 0884-8734

IS - 8

ER -